Clinical Trials · NCT00383708

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Name: Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lanreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 125
Start date: Oct 2006
Locations: 24 sites, 10 countries
Primary endpoint: Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period

View Lanreotide compound reference